KR20200079605A - Balloon catheter having chitosan hemostatic material - Google Patents

Abstract

Disclosed is a balloon catheter including a chitosan hemostatic material. According to the present invention, the balloon catheter including a chitosan hemostatic material comprises: a catheter including one or more tubes and inserted into the body to be extended to an application portion; a balloon attached to surround the catheter and expanded or unfolded at the application portion to compress a bleeding portion; and the chitosan hemostatic material attached to the outer surface of the balloon. The catheter comprises: an expansion inducing agent tube transferring an expansion induction agent for expanding or unfolding the balloon to the balloon; and a drug pipe penetrating the balloon and transferring drug for coating the application portion. Accordingly, physical hemostasis and chemical hemostasis are performed at the same time, thereby significantly reducing hemostasis time.

Description

Balloon catheter having chitosan hemostatic material

The present invention relates to a hemostatic material, and in particular, to a balloon catheter comprising a chitosan hemostatic material for responding to post-bleeding during cervical biopsy, cone resection or gynecological surgery, procedure or examination.

Post-bleeding may occur during cervical biopsy, cone resection or gynecological surgery, procedure or examination. In particular, after delivery, the wall of the uterus is strongly contracted to prevent bleeding by compressing blood vessels entering the uterus. If this series of processes does not occur smoothly, hemostasis may not occur.

For example, there may be bleeding of 500 cc or more after the placenta falls off after delivery of a newborn baby, and this is called postpartum bleeding. Postpartum bleeding is considered to be the leading cause of maternal death in which the mother dies after delivery. In particular, the number of older pregnant women is increasing due to the late marriage, and it is known that older mothers are more likely to postpartum bleeding.

If postpartum bleeding occurs, a blood transfusion is used to massage the bottom of the uterus, and a uterine contractor is used to induce bleeding. However, not all pregnant women respond effectively to these treatments, and if bleeding continues despite these treatments, surgery may be needed to remove the uterus. If the uterus is removed, the pregnant woman can live, but no further pregnancy is possible.

Methods of bleeding postpartum bleeding while avoiding hysterectomy include intrauterine balloon dilation and uterine artery embolization. Uterine artery embolization is a method of blocking the supply of blood by using a special thrombus material (gel foam) in the uterine arteries on both sides that supply blood to the uterus. In addition, intrauterine balloon dilation compression is to insert a balloon catheter into the bleeding site, then inflate the balloon to compress the blood vessels so as to stop bleeding.

Republic of Korea Patent Application Publication No. 10-20160021959 filed on August 18, 2014 (invention name: "multi-balloon catheter and catheter device having the same") includes: a support tube in which a chemical liquid passage and an expansion fluid passage are formed; A steering tube integrally formed with an extended end of the support tube, having a connection passage and an induction passage, and two or more side holes are arranged on the side of the induction passage; A tip fixed to a front end portion of the steering tube; A balloon sheet fixed in close contact with the outer circumferential surface of the steering tube and expandable in a radial direction of the steering tube by the pressure of the expanding fluid injected through the side hole; Disclosed is a balloon catheter that takes the form of a ring and includes three or more shrink rings that partially secure the balloon seat to the outer circumferential surface of the steering tube. According to this balloon catheter, even if the narrowing region is wide or the inner shape of the narrowing region is irregular, the narrowed narrowing region can be opened simultaneously, so the procedure is quick and thus the procedure effect can be increased.

However, when the balloon catheter of the prior art is used for hemostasis, the effect does not necessarily appear immediately. The reason is that it takes time to inflate the balloon catheter of the prior art and compress the blood vessel.

Therefore, there is an urgent need for a technique to protect the life of a precious pregnant woman while significantly reducing the time required for hemostasis by simultaneously attempting chemical hemostasis by drugs in addition to physical compression hemostasis.

Republic of Korea Patent Application Publication No. 10-20160021959 (Name of invention: "Multi-balloon catheter and catheter device having the same")

It is an object of the present invention to provide a balloon catheter by simultaneously adding a hemostatic agent using chitosan to the balloon catheter, and simultaneously pursuing the hemostatic effect by the balloon catheter and the chemical hemostatic effect by the hemostat.

One aspect of the present invention for achieving the above object, relates to a balloon catheter comprising a chitosan hemostat. The balloon catheter comprising the chitosan hemostatic agent according to the present invention includes one or more conduits, a catheter inserted into a human body and extended to an application site; A balloon that is attached to surround the catheter and expands or develops at the application site to compress the bleeding site; And a chitosan haemostatic agent attached to the outer surface of the balloon. In particular, the catheter includes an expansion inducer conduit that delivers an expansion inducer for expanding or deploying the balloon to the balloon; And a medicament conduit penetrating the balloon and delivering medicament for application to the application site. Furthermore, the balloon comprises a film film containing an inflation inducer, and the film film is made of a material that expands when the inflation inducer is injected and compresses the bleeding site. Alternatively, the balloon includes a film film containing an inducing agent, and the film film includes a plurality of developing parts interconnected to communicate the infusing agent, and the developing part is deployed when the infusing agent is injected to compress the bleeding site. It is characterized by being made of a material that can. Preferably, the balloon catheter is formed in a shape surrounding the upper portion of the chitosan hemostat, further comprising a protective tube to protect the balloon and the chitosan hemostat, the protective tube, the balloon and the chitosan to the application site The hemostat is guided, and when the balloon catheter reaches the application site, it is separated from the chitosan hemostat and is removed along the catheter in a direction opposite to the insertion direction. Further, the chitosan hemostatic material includes at least one outer skin part and at least one inner skin part, and the outer skin part comprises 30 to 100 parts by weight of chitosan yarn, 0 to 70 parts by weight of basic yarn, and 0 to 50 parts by weight of functional material. It is characterized by being in the form of a woven fabric. In addition, the inner skin is characterized in that it is a woven fabric form or a bundle form including 0 to 100 parts by weight of chitosan yarn and 0 to 50 parts by weight of functional material relative to 100 parts by weight of the basic yarn. Preferably, the basic yarn is one of cotton, lyocell (Lyocell), rayon, acetate, tencel (Tencell), cellulose and oxidized regenerated cellulose, or a mixture of two or more thereof, and the functional material is alginate (Alginate) It is characterized by being used. In particular, the outer skin and the inner skin are characterized by having different chitosan content ratios or different density ratios, and it is preferable that the chitosan content and density of the endothelial skins have relatively lower values. In addition, the inner skin portion, the top of the sheet layer further includes a central material in the form of a circular bundle, characterized in that it is filled in the center of the outer skin portion. In particular, the inner skin is characterized by having different chitosan content ratios or different density ratios, and the chitosan content and density may be relatively lower as it is positioned inside the outer skin. In particular, the outer skin is characterized in that the mesh member is formed on the inside or outside.

According to the present invention, since the chitosan-based chitosan haemostatic agent is attached to the balloon surface of the balloon catheter, rapid hemostasis is possible by simultaneously performing hemostasis by the hemostatic agent as well as compression hemostasis by the balloon catheter.

Therefore, it is possible to minimize the loss of life due to mass bleeding.

1 is a cross-sectional view showing before and after expansion of a balloon catheter comprising a chitosan hemostatic agent according to the present invention.
2 is a cross-sectional view showing before and after the balloon catheter comprising the chitosan hemostat according to the present invention is deployed.
3 is a plan view of the balloon catheter including the chitosan hemostat shown in FIG. 2, as viewed from above.
4 is a view briefly showing the configuration of a chitosan hemostat attached to a balloon catheter comprising the chitosan hemostat according to the present invention.

In order to fully understand the present invention, the operational advantages of the present invention, and the objects achieved by the practice of the present invention, reference should be made to the accompanying drawings and the contents described in the accompanying drawings, which illustrate preferred embodiments of the present invention.

Hereinafter, the present invention will be described in detail by explaining preferred embodiments of the present invention with reference to the accompanying drawings. However, the present invention may be implemented in various different forms, and is not limited to the described embodiments. In addition, in order to clearly describe the present invention, parts irrelevant to the description are omitted, and the same reference numerals in the drawings indicate the same members.

1 is a cross-sectional view showing before and after expansion of a balloon catheter comprising a chitosan hemostatic agent according to the present invention. FIG. 1(a) is a view before the balloon catheter 100 including the chitosan hemostat is expanded, and FIG. 1(b) is a view before the balloon catheter 100 containing the chitosan hemostat is expanded.

1, the balloon catheter 100 of the present invention includes a balloon 150, a conduit 192, 194, and a chitosan hemostat 130.

The balloon 150 is attached to surround the conduits 192 and 194, and expands or expands at an application site necessary for the human body to compress the bleeding site. In FIG. 1, two conduits 192 and 194 are exemplified, one of which is an expansion inducer conduit 192 for supplying the balloon 150 with an expansion inducing agent for expanding or deploying the balloon 150, and the other. It is a drug conduit 194 that penetrates the balloon 150 and delivers the drug for application to the application site. However, this is for example only, and depending on the type of drug to be administered, there may be three or more conduits.

The balloon 150 is made of a non-flexible material such as polyethylene terephthalate (PET), irradiated polyethylene or nylon. For the use described above, the thickness of the material can be within the range of 0.005 to 0.02" (0.13 to 5 mm) to provide an expanding balloon 150 that applies sufficient force to the conduit wall without causing rupture.

The balloon 150 of the illustrated embodiment can be manufactured using known techniques.

One method involves heating the tube of PET and then expanding the material in the stretch and mold to create a desired final shape. As an example, a tube having an outer diameter of 0.150 inches (3.8 mm) and a wall thickness of 0.008 to 0.015 inches (0.2 to 0.38 mm) can be used to make a 14-16-18 mm diameter balloon 150. After convective heating of the central portion of the tube for about 15 to 45 seconds, the heat source is retracted and a fully expanded shaped mold of balloon 150 is placed over the tube. The tube extends along the longitudinal axis to form a thin wall portion corresponding to the final shape of the balloon 150.

In this position, pressurized gas is introduced through one end of the tube, and the tube is sealed at the other end, whereby the heated tube is expanded to conform to the inner surface of the mold. After a brief interval, when the mold is retracted, the gas is partially released to a point above 1 atm so that the balloon 150 remains in an expanded state in its expanded shape. After a brief cooling period, the balloon 150 is removed and ready to bond to the catheter. In a preferred embodiment, PET balloon 150 is bonded to a catheter made of polyurethane using a UV adhesive. Other good medical device adhesives can also be used.

Of course, the balloon catheter 100 of the present invention can be manufactured in many known ways in addition to the above-described examples.

Chitosan haemostatic material 130 attached to the surface of the balloon 150 contains chitosan. Chitosan is a material that is in the spotlight as a biopolymer, and is not soluble in water, but has cationic properties, and has attracted attention as a medical material and a natural antibacterial agent because it has a biocompatibility and a wound healing promoting action.

In particular, it is known that the wound healing ability is excellent, and it is proved that the wound healing ability is excellent because the cation of chitosan binds to the bacterial anion to prevent the adhesion of bacterial cells to other biological tissues. The composition and the like of the chitosan haemostatic material 130 will be described in detail with reference to FIG. 4. Therefore, repeated descriptions are omitted for the sake of brevity.

FIG. 1(b) shows the balloon catheter 100 expanded after reaching the application site. When the expansion inducer is introduced through the expansion inducer conduit 192, the balloon 150 expands to compress the application site. At this time, since the chitosan haemostatic agent 130 attached to the outer surface of the balloon 150 applies a drug that helps hemostasis to the corresponding site, the hemostatic effect can be increased.

2 is a cross-sectional view showing before and after the balloon catheter comprising the chitosan hemostat according to the present invention is deployed. FIG. 2(a) is a view before the balloon catheter 200 including the chitosan hemostat is deployed, and FIG. 2(b) shows the protection tube 170 in the balloon catheter 200 containing the chitosan hemostat. It shows the process to be removed, Figure 3 (c) shows the state after the balloon catheter 100 including chitosan hemostatic material is deployed.

2, the balloon catheter 200 of the present invention includes a balloon 150, a conduit 192, 194, a chitosan hemostat 130, and a protective tube 170. The difference between the balloon catheter 100 of FIG. 1 and the balloon catheter 200 including the chitosan hemostat of FIG. 2 is that the balloon catheter 200 of FIG. 2 includes a protective tube 170, and the balloon of FIG. 2 The catheter is deployed rather than dilated, compressing the application site.

In (a) of FIG. 2, the balloon 150 includes a deployment line 153. That is, the balloon 150 of FIG. 2 is stored in the protective tube 170 in a folded state along the deployment line 153, and is moved to the application site in the human body along the guide wire in this state.

Figure 2 (b) shows the process of removing the protective tube 170 from the balloon catheter 200 containing the chitosan hemostat after reaching the application site. The protective tube 170 is extracted in the reverse direction along the conduits 192 and 194 as opposed to the inserted method. The arrow of FIG. 2B indicates the direction in which the protective tube 170 is extracted.

When the protective tube 170 is removed from the balloon catheter 200, the balloon 150 and the chitosan hemostat 130 attached to the balloon 150 in a folded state along the deployment line 153 as shown in FIG. 2(b) ) Is left.

Referring now to FIG. 2(c), the expansion inducer is injected into the balloon 150 through the expansion inducer conduit 192, and then the balloon 150 is deployed along the deployment line 153 to compress the application site. do. In the present invention, a fluid harmless to the human body, such as water, gas, or saline, may be used as the expansion inducer. The balloon 150 may include a film film (not shown) for storing the expansion inducer.

To provide sufficient stiffness to the balloon catheter, a wire guide (not shown) may be included in the balloon 150 and the catheter's conduit. In this case, the wire guide does not completely fill the conduit so that the fluid properly traverses the conduit to expand the balloon. As shown in FIG. 2, a multi-conduit catheter may be used so that a wire guide can be disposed in a conduit separate from the expansion conduit. Although a standard stainless steel wire guide can be used, a good wire guide material is a superelastic alloy such as Nitinol (NiTi alloy). The 0.023 inch (0.58mm) diameter nitinol wire guide provides good stiffness for introduction into the human body and cannulation of the stenosis, while maintaining high flexibility within the twisted path. The wire guide may include end portions coated or coated with a polymer such as polyurethane. To make the distal portion more intact, the nitinol wire guide may be formed with a gradual taper across the distal 5 cm of the device.

In FIG. 2, only two vertical lines are illustrated, but this does not limit the present invention. That is, the development line 153 may have various patterns to fit the shape of the application site.

In addition, although the balloon 150 is shown in FIG. 2 after the protective tube 170 is completely removed, the protective tube 170 may be removed and the balloon 150 may be simultaneously deployed. For example, after only a portion of the protective tube 170 is removed, the protective tube 170 may naturally move downward according to the development of the balloon 150.

3 is a plan view of the balloon catheter including the chitosan hemostat shown in FIG. 2, as viewed from above.

As shown in FIG. 3, the balloon catheter comprising chitosan hemostatic material is installed to surround the conduits 192, 194, and the conduits 192, 194, and the balloon 150 can be expanded or expanded by an expansion inducer. , Chitosan haemostatic material 130 attached to the outer surface of the balloon 150, and a protective tube 170 surrounding the chitosan haemostatic material 130.

As described above, the expansion inducer conduit 192 is for injecting the expansion inducer, and the medication conduit 194 is for injecting a separate medication to be applied to the application site.

As shown in FIG. 3, upon arrival at the application site, the protective tube 170 is removed, and the chitosan haemostatic material 130 directly compresses the application site by expansion or deployment of the balloon 150. Therefore, along with physical hemostasis by compression, chemical hemostasis by the chitosan hemostatic material 130 occurs simultaneously.

In the present specification, the application site is a term for an indication having a bleeding site having a special shape such as a deep bleeding site, a special flexion site, a lesion site, or a site where mass bleeding occurs, and the cervix is particularly included in the application site.

As described above, the balloon catheter comprising the chitosan hemostatic agent according to the present invention has a very excellent effect of hemostatic performance and compression performance because it is customized to the application site of the patient.

4 is a view briefly showing the configuration of a chitosan hemostat attached to a balloon catheter comprising the chitosan hemostat according to the present invention.

The chitosan hemostatic material shown in FIG. 4 is constructed based on chitosan, and is intended to improve properties such as hemostatic power, antibacterial power, absorption power, and biological stability, while improving absorption power, mechanical properties, and shape stability.

In particular, the chitosan hemostatic material 130 shown in FIG. 4 may be formed in a three-dimensional shape as well as a flat shape such as a dressing material or gauze. In this case, effective hemostasis and compression are possible even in an indication having a specially shaped bleeding site, such as a deep bleeding site, a special flexion site, a lesion site or a mass bleeding site.

The chitosan haemostatic material 130 may be formed of a material having various structures or materials having various components and densities depending on the application site. As shown in FIG. 4, the chitosan hemostatic material 130 may be composed of an outer skin 110 and an inner skin 120 filled inside the outer skin 110.

Here, since the outer skin 110 is directly in contact with the bleeding site, hemostatic performance is at least equal to or higher than that of the inner skin 120, and the inner skin 120 is prevented from being gelled and torn by blood or water. Use a material with at least the same density.

The outer skin 110 uses chitosan-based material to improve hemostasis performance, and it is particularly preferable to use a fabric formed by weaving chitosan yarn in a non-woven form. Further, in order to improve mechanical properties, shape stability, durability, biological stability, and functionality, a basic yarn may be added to the chitosan yarn, or a woven fabric may be used by adding a functional material.

Specifically, the outer skin 110 is a woven fabric form including 30 to 100 parts by weight of chitosan yarn, 0 to 70 parts by weight of basic yarn, and 0 to 50 parts by weight of functional material, or the inner skin 120 is 100 of basic yarn It may be in the form of a woven fabric or a bundle, including 0 to 100 parts by weight of chitosan yarn and 0 to 50 parts by weight of functional material relative to parts by weight.

These composition ratios can be adjusted according to the type, type, purpose, use, and amount of bleeding. However, when using the chitosan yarn smaller than 30 parts by weight in the outer skin 110, the performance of chitosan may not be properly expressed.

The inner skin 120 does not contain chitosan, and may be implemented only with basic yarn (100 parts by weight of chitosan for outer skin 110, 100 parts by weight of basic yarn (cotton) for inner skin 120), type or purpose of application site , It can be used by adjusting the composition ratio of basic yarn, chitosan yarn, functional material, etc. according to the use, bleeding amount, and the like.

In the present invention, as described above, the chitosan content or density of the outer skin part 110 directly contacting the application site is formed to be high, and the inner skin part 120 is equal to or compared to the content or density of the outer skin part 110. It is formed to have a low chitosan content and density. If necessary, the inner skin 120 may be composed of only basic yarn.

In addition, the inner skin 120 may be implemented by stacking a plurality of sheet layers 121 or in a bundle form. In addition, the central portion 122 in the form of a circular bundle on the top of the sheet layer 121 is further included, it may be filled in the center of the outer skin portion 110. It may be formed by variously controlling the shape of the application site or the amount of bleeding.

In addition, the inner skin 120 may be formed to have different chitosan content ratios or different density ratios when the plurality of sheet layers 121 or the center material 122 is provided, and the outer skin 110 The chitosan content and density are relatively lower as it is located inside the vessel.

As described above, the chitosan hemostatic material 130 according to the present invention may be formed in a shape corresponding to the shape of the balloon 150, and provided with a plurality of sheet layers 121 inside the outer skin portion 110 formed in the balloon shape. The inner skin 120 is filled, or the inner skin 120 provided with the core material 122 in the form of a bundle in one sheet layer 121 is filled, or the inner skin 120 is packed in a plurality of sheet layers 121 (top layer). The inner skin 120 provided with the form of the core material 122 may be filled, and may be embodied in various embodiments as described above according to the type, type, bleeding amount, use, purpose, etc. of the application site.

Here, the basic yarn may use various fiber yarns according to the type of application site, purpose or use, and natural fibers or synthetic fibers may be used. Specifically, any one of biocompatible cotton, lyocell, rayon, acetate, tencel, cellulose and oxidized regenerated cellulose, or a mixture of two or more thereof may be used.

By using these basic yarns, characteristics such as absorbency, mechanical properties, shape stability, and biological stability are expressed, and characteristics such as active hemostatic performance, absorbency, antibacterial activity, and biological stability are expressed by the chitosan yarn.

Therefore, it is expected that by using these two materials together, mutual functions will be complemented and improved, resulting in superior price competitiveness and medical utility.

In addition, the functional material may be added according to the type, purpose, or application of the application site to these materials, and preferably, alginate may be used. The alginate is a material extracted from brown algae, can maintain a water-soluble and moist environment, and has a property of adsorbing toxicity, and thus may be used to supplement a specific function.

The basic yarn and chitosan yarn in the present invention are characterized by using staple fibers formed with a crimp number of 12 to 15 pieces/inch.

Klimp means to give a'V'-shaped or zigzag-shaped bend to the yarn, and the yarn formed by cutting the crimped yarn at intervals of 1 to 3 inches is called a staple fiber.

The number of wrinkles per inch of this staple fiber is called the crimp number, and the preferred crimp number of the basic yarn and chitosan yarn of the present invention is 12 to 15/inch.

The crimp water is implemented by controlling processing conditions such as a crimp processing facility, arrangement of a gear for bending, heat treatment temperature, time, etc., thereby improving the surface density of the product to further enhance appearance, absorbency, and other performance.

When a large number of such crimps is provided, physical properties, in particular, tensile strength, breaking strength, and tear strength are increased due to increased binding between yarns during manufacturing, and the pore size of the fiber structure is uniform. In addition, due to the uniform density, the surface area of the yarn is increased (the contact area is increased), and the chemical performance of chitosan is further increased.

That is, even with 100% chitosan, if the density is non-uniform, the yarn surface area is relatively low, and the effect of hemostasis or gelation by reacting with blood or water may be non-uniform or reduced. Evenly, the density is evenly contributed to the improvement of its properties.

The number of crimps of the basic yarn and chitosan yarn according to the present invention is 12 to 15/inches. If it is lower than this, the yarn falls off when weaving into the fiber, and the yield decreases or the surface has non-uniform characteristics. The binding effect caused by the deterioration is reduced, and it is not possible to contribute to the improvement of strength. Meanwhile, the alginate used as the functional material also uses a yarn having a similar crimp number.

Accordingly, the present invention can exhibit the same level of hemostatic performance even if the chitosan content is lowered compared to the existing 100% chitosan fiber, and as the chitosan content is reduced, each additional material is separately added by adding materials such as basic yarn and alginate. It is to be able to express the functions of the form (form retention, toxic adsorption, etc.) at the same time.

Here, the thickness of the basic yarn, chitosan yarn, and alginate is 1.0 to 5.0 Denier, and the thickness is adjusted according to the purpose or purpose.

On the other hand, the outer skin 110 may be formed by laminating a mesh member 115 on the inner or outer side, and is preferably manufactured in a manner of consolidating on the inner side of the outer skin 110.

The mesh member 115 is intended to improve the shape stability, durability, and strength of the outer skin 110, and prevents the outer skin 110 from being torn by blood or water when it is gelled. It is for.

The mesh member 115 is formed of a two-layer or three-layer structure on the outer or inner side of the outer skin 110 using a mesh (or scrim) woven from cotton or high-strength yarn with a fabric or knitted fabric.

The mesh member 115 is a gauze or bandage fabric woven from a material such as cotton or lyocell, and may be set as a drug or quasi-drug.

The balloon catheter 100 prepared according to one embodiment of the present invention has a blood absorption power of 10-30 g (times), a blood cohesive power of 40-90%, an antibacterial power of 99.9% (pneumococcal, Staphylococcus aureus), and a tensile force of 5-50 kgf/50 mm It is expected to have excellent bleeding ability, absorbency, antibacterial activity, and form stability such as physical strength.

As described above, the present invention provides chitosan hemostatic material for responding to bleeding during cervical biopsy, anal surgery, single-hole surgery, single-hole laparoscopic surgery, special flexion surgery site, hemorrhoids, cone resection or gynecological surgery, procedure or examination. It is about the balloon catheter to include.

In addition, the present invention allows the various designs to be applied to various application sites by adjusting the chitosan content or density of the outer and inner skins differently to allow various designs in consideration of absorption power, absorption time, and hemostasis mechanism.

In addition, by varying the content ratio of the materials constituting the inner skin and the outer skin, the density difference between the inner skin and the outer skin, the type of material used in the inner skin, and the type of material used in the outer skin, and adjusting their content ratio It is applied in response to various application sites, and is designed to control absorption power and absorption time.

In addition, the material used for the inner skin, the material used for the outer skin, or their content ratio can be adjusted, or the weaving method of the inner skin and the outer skin (knit, fabric, fabric) can be changed.

Although the present invention has been described with reference to the embodiments shown in the drawings, these are merely exemplary, and those skilled in the art will understand that various modifications and other equivalent embodiments are possible therefrom.

In the terminology used herein, a singular expression should be understood to include a plurality of expressions unless the context clearly indicates otherwise, and terms such as “comprises” describe features, numbers, steps, operations, and components described. It is to be understood that it means that a part or a combination thereof is present, and does not exclude the presence or addition possibility of one or more other features or numbers, step operation components, parts or combinations thereof. In addition, terms such as "... part", "... group", "module", and "block" described in the specification mean a unit that processes at least one function or operation, which is hardware or software or hardware. And software.

Therefore, the drawings attached to the present embodiment and the present specification are merely a part of the technical spirit included in the present invention, and those skilled in the art within the scope of the technical spirit included in the specification and the drawings of the present invention can easily It will be apparent that both the modified examples and the specific examples that can be inferred are included in the scope of the present invention.

The present invention has the advantage of being able to hemostatically adhere to the uterine or other curved bleeding area, and thus can be applied to various procedures, and in particular, it can be applied to arterial embolization as well as balloon expansion compression.

100, 200: balloon catheter containing chitosan hemostat
110: outer skin 115: mesh member
120: inner skin 121: sheet layer
122: core material 130: chitosan hemostatic material
150: balloon 153: development line
170: protective tube 192, 194: conduit

Claims (15)

In the balloon catheter comprising a chitosan hemostat,
A catheter that includes one or more conduits and is inserted into the human body and extends to the application site;
A balloon that is attached to surround the catheter and expands or develops at the application site to compress the bleeding site; And
A balloon catheter comprising a chitosan hemostat, comprising a chitosan hemostat attached to the outer surface of the balloon. According to claim 1,
The catheter,
An expansion inducer conduit that delivers an expansion inducer for expanding or deploying the balloon to the balloon; And
A balloon catheter comprising a chitosan haemostatic material penetrating the balloon and comprising a medicament conduit for delivering a medicament for application to the application site. According to claim 1,
The balloon includes a film film containing an inducing agent,
The film membrane is inflated when the inflation inducer is injected, characterized in that it is made of a material that can compress the bleeding site, balloon catheter comprising a chitosan hemostat. According to claim 1,
The balloon includes a film film containing an inducing agent,
The film layer includes a plurality of deployment parts interconnected to communicate the expansion inducer,
The expansion portion is deployed when the inflation inducer is injected, characterized in that it is made of a material that can compress the bleeding site, balloon catheter comprising a chitosan hemostat. According to claim 4,
The balloon catheter further includes a protective tube that is formed in a shape surrounding the upper portion of the chitosan hemostat to protect the balloon and the chitosan hemostat,
The protective tube guides the balloon and the chitosan hemostat to the application site, and when the balloon catheter reaches the application site, it is separated from the chitosan hemostat and removed along the catheter in a direction opposite to the insertion direction. A balloon catheter comprising a chitosan haemostatic material, characterized in that. According to claim 1,
The chitosan hemostatic material includes at least one outer skin and at least one inner skin,
The outer skin is 30 to 100 parts by weight of chitosan yarn, 0 to 70 parts by weight of basic yarn, and 0 to 50 parts by weight of functional material. The method of claim 6,
The endothelial skin is a balloon catheter comprising a chitosan hemostatic material, characterized in that the woven fabric form or a bundle form including 0 to 100 parts by weight of chitosan yarn and 0 to 50 parts by weight of functional material relative to 100 parts by weight of the basic yarn. The method of claim 6,
The basic yarn is one of cotton, lyocell, rayon, acetate, tencel, cellulose, and oxidized regenerated cellulose, or a mixture of two or more of them, and is used.
The functional material is characterized in that using alginate (Alginate), balloon catheter comprising a chitosan haemostatic material. The method of claim 6, wherein the outer skin and inner skin,
Balloon catheters comprising a chitosan haemostatic material, characterized in that they have different chitosan content ratios or different density ratios. The method of claim 9, wherein the outer skin and inner skin,
A balloon catheter comprising a chitosan haemostatic material, characterized in that the chitosan content and density of the endothelial skin relative to the outer skin are relatively lower. The method of claim 6, wherein the inner skin,
A balloon catheter comprising a chitosan haemostatic material, characterized in that a plurality of sheet layers are stacked. The method of claim 11, wherein the inner skin,
A balloon catheter comprising a chitosan hemostat, characterized in that the top of the sheet layer further includes a central material in the form of a circular bundle, and is filled in the center of the outer skin. The method of claim 11 or 12, wherein the inner skin,
Balloon catheters comprising a chitosan haemostatic material, characterized in that they have different chitosan content ratios or different density ratios. The method of claim 13, wherein the inner skin,
A balloon catheter comprising a chitosan haemostatic material, characterized in that the chitosan content and density are relatively lower as it is located inside the outer skin. The method of claim 6, wherein the outer skin,
A balloon catheter comprising a chitosan hemostat, characterized in that the mesh member is formed on the inside or outside.

Images